Onasemnogene Abeparvovec Injectable Suppliers & Bulk Manufacturers
Available Forms: Injectable gene therapy
Available Strengths: Single-dose IV infusion providing 6 x 10^13 vector genomes (vg) per patient
Reference Brands: Zolgensma(US & EU)
Category: Cell & Gene Therapies
Onasemnogene abeparvovec (Zolgensma) delivers a functional copy of the SMN1 gene via gene therapy, increasing SMN protein production. It improves motor function, prolongs survival, and reduces the need for ventilatory support in SMA patients. Offers a one-time, lifelong treatment for early intervention in SMA.
Product Description:
Onasemnogene abeparvovec (Zolgensma) is regulated in both the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality following GMP standards. In the US, FDA approval involved extensive clinical trials, safety evaluations, and GMP compliance. In the EU, CE marking certifies conformity with MDR standards for pediatric spinal muscular atrophy (SMA) treatment. These therapies undergo validation, stability testing, and audits, with detailed documentation including clinical trial data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance grants access to innovative, life-changing gene therapy for SMA worldwide, supporting early intervention and improved long-term outcomes.
Onasemnogene Abeparvovec Injectable — third party manufacturing & bulk supply
Onasemnogene Abeparvovec Injectable is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Onasemnogene Abeparvovec Injectable is supplied as Injectable gene therapy — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Onasemnogene Abeparvovec Injectable listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Onasemnogene Abeparvovec Injectable →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Darleukin Injection
Strength:
A standardized dose of 120 million adipose-derived stem cells per injection
Form: Intralesional injection
Reference Brands: Alofisel(US & EU)
View Details
Etranacogene Dezaparvovec. Infusion
Strength:
Single infusion product designed to produce sustained factor IX levels in hemophilia B patients, dosage individualized based on patient weight
Form: Intravenous infusion
Reference Brands: Hemgenix (US & EU)
View Details
Elivaldogene Autotemcel Infusion
Strength:
A personalized gene therapy designed to halt or slow ALD progression, dosed based on weight, administered as a single infusion in specialized treatment centers
Form: Intravenous infusion
Reference Brands: Skysona(US & EU)
View Details
Valoctocogene Roxaparvovec Infusion
Strength:
A single-dose gene therapy designed to increase factor VIII production in hemophilia A patients
Form: Intravenous infusion
Reference Brands: Roctavian(US & EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
